ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Inactivated Vaccine Market Research Report 2025
Published Date: January 2025
|
Report Code: QYRE-Auto-1G6415
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Inactivated Vaccine Market Insights and Forecast to 2028
BUY CHAPTERS

Global Inactivated Vaccine Market Research Report 2025

Code: QYRE-Auto-1G6415
Report
January 2025
Pages:76
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson& Johnson (U.S.)
MedImmune (U.S.)
Merck& Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)

Inactivated Vaccine Market Size

The global market for Inactivated Vaccine was valued at US$ 6209 million in the year 2024 and is projected to reach a revised size of US$ 7768 million by 2031, growing at a CAGR of 3.3% during the forecast period.

Inactivated Vaccine Market

Inactivated Vaccine Market

Inactivated vaccines are viruses or bacteria that are first cultured and then inactivated with heat or chemicals. Inactivated vaccines may consist of whole viruses or bacteria, or they may consist of fragments that cleave together to form a cleaved vaccine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Inactivated Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Inactivated Vaccine.
The Inactivated Vaccine market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Inactivated Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Inactivated Vaccine companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation

Scope of Inactivated Vaccine Market Report

Report Metric Details
Report Name Inactivated Vaccine Market
Accounted market size in year US$ 6209 million
Forecasted market size in 2031 US$ 7768 million
CAGR 3.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
Segment by Application
  • Hospital
  • Medical Center
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Astellas Pharma(Japan), CSL Limited(Australia), Emergent BioSolutions(U.S.), GlaxoSmithKline(U.K.), Johnson & Johnson(U.S.), MedImmune(U.S.), Merck & Co(U.S.), Pfizer(U.S.), Sanofi Pasteur(France), Serum Institute of India Pvt(India)
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Inactivated Vaccine company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Inactivated Vaccine Market growing?

Ans: The Inactivated Vaccine Market witnessing a CAGR of 3.3% during the forecast period 2025-2031.

What is the Inactivated Vaccine Market size in 2031?

Ans: The Inactivated Vaccine Market size in 2031 will be US$ 7768 million.

Who are the main players in the Inactivated Vaccine Market report?

Ans: The main players in the Inactivated Vaccine Market are Astellas Pharma(Japan), CSL Limited(Australia), Emergent BioSolutions(U.S.), GlaxoSmithKline(U.K.), Johnson & Johnson(U.S.), MedImmune(U.S.), Merck & Co(U.S.), Pfizer(U.S.), Sanofi Pasteur(France), Serum Institute of India Pvt(India)

What are the Application segmentation covered in the Inactivated Vaccine Market report?

Ans: The Applications covered in the Inactivated Vaccine Market report are Hospital, Medical Center

What are the Type segmentation covered in the Inactivated Vaccine Market report?

Ans: The Types covered in the Inactivated Vaccine Market report are Children Inactivated Vaccine, Adult Inactivated Vaccine

Recommended Reports

Vaccine Technology

Vaccine Ancillary Markets

Pediatric Vaccines

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Inactivated Vaccine Market Size Growth Rate by Type: 2020 VS 2024 VS 2031
1.2.2 Children Inactivated Vaccine
1.2.3 Adult Inactivated Vaccine
1.3 Market by Application
1.3.1 Global Inactivated Vaccine Market Growth by Application: 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Medical Center
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Inactivated Vaccine Market Perspective (2020-2031)
2.2 Global Inactivated Vaccine Growth Trends by Region
2.2.1 Global Inactivated Vaccine Market Size by Region: 2020 VS 2024 VS 2031
2.2.2 Inactivated Vaccine Historic Market Size by Region (2020-2025)
2.2.3 Inactivated Vaccine Forecasted Market Size by Region (2026-2031)
2.3 Inactivated Vaccine Market Dynamics
2.3.1 Inactivated Vaccine Industry Trends
2.3.2 Inactivated Vaccine Market Drivers
2.3.3 Inactivated Vaccine Market Challenges
2.3.4 Inactivated Vaccine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Inactivated Vaccine Players by Revenue
3.1.1 Global Top Inactivated Vaccine Players by Revenue (2020-2025)
3.1.2 Global Inactivated Vaccine Revenue Market Share by Players (2020-2025)
3.2 Global Inactivated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Inactivated Vaccine Revenue
3.4 Global Inactivated Vaccine Market Concentration Ratio
3.4.1 Global Inactivated Vaccine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Inactivated Vaccine Revenue in 2024
3.5 Global Key Players of Inactivated Vaccine Head office and Area Served
3.6 Global Key Players of Inactivated Vaccine, Product and Application
3.7 Global Key Players of Inactivated Vaccine, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Inactivated Vaccine Breakdown Data by Type
4.1 Global Inactivated Vaccine Historic Market Size by Type (2020-2025)
4.2 Global Inactivated Vaccine Forecasted Market Size by Type (2026-2031)
5 Inactivated Vaccine Breakdown Data by Application
5.1 Global Inactivated Vaccine Historic Market Size by Application (2020-2025)
5.2 Global Inactivated Vaccine Forecasted Market Size by Application (2026-2031)
6 North America
6.1 North America Inactivated Vaccine Market Size (2020-2031)
6.2 North America Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
6.3 North America Inactivated Vaccine Market Size by Country (2020-2025)
6.4 North America Inactivated Vaccine Market Size by Country (2026-2031)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Inactivated Vaccine Market Size (2020-2031)
7.2 Europe Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
7.3 Europe Inactivated Vaccine Market Size by Country (2020-2025)
7.4 Europe Inactivated Vaccine Market Size by Country (2026-2031)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Inactivated Vaccine Market Size (2020-2031)
8.2 Asia-Pacific Inactivated Vaccine Market Growth Rate by Region: 2020 VS 2024 VS 2031
8.3 Asia-Pacific Inactivated Vaccine Market Size by Region (2020-2025)
8.4 Asia-Pacific Inactivated Vaccine Market Size by Region (2026-2031)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Inactivated Vaccine Market Size (2020-2031)
9.2 Latin America Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
9.3 Latin America Inactivated Vaccine Market Size by Country (2020-2025)
9.4 Latin America Inactivated Vaccine Market Size by Country (2026-2031)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Inactivated Vaccine Market Size (2020-2031)
10.2 Middle East & Africa Inactivated Vaccine Market Growth Rate by Country: 2020 VS 2024 VS 2031
10.3 Middle East & Africa Inactivated Vaccine Market Size by Country (2020-2025)
10.4 Middle East & Africa Inactivated Vaccine Market Size by Country (2026-2031)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Astellas Pharma(Japan)
11.1.1 Astellas Pharma(Japan) Company Details
11.1.2 Astellas Pharma(Japan) Business Overview
11.1.3 Astellas Pharma(Japan) Inactivated Vaccine Introduction
11.1.4 Astellas Pharma(Japan) Revenue in Inactivated Vaccine Business (2020-2025)
11.1.5 Astellas Pharma(Japan) Recent Development
11.2 CSL Limited(Australia)
11.2.1 CSL Limited(Australia) Company Details
11.2.2 CSL Limited(Australia) Business Overview
11.2.3 CSL Limited(Australia) Inactivated Vaccine Introduction
11.2.4 CSL Limited(Australia) Revenue in Inactivated Vaccine Business (2020-2025)
11.2.5 CSL Limited(Australia) Recent Development
11.3 Emergent BioSolutions(U.S.)
11.3.1 Emergent BioSolutions(U.S.) Company Details
11.3.2 Emergent BioSolutions(U.S.) Business Overview
11.3.3 Emergent BioSolutions(U.S.) Inactivated Vaccine Introduction
11.3.4 Emergent BioSolutions(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
11.3.5 Emergent BioSolutions(U.S.) Recent Development
11.4 GlaxoSmithKline(U.K.)
11.4.1 GlaxoSmithKline(U.K.) Company Details
11.4.2 GlaxoSmithKline(U.K.) Business Overview
11.4.3 GlaxoSmithKline(U.K.) Inactivated Vaccine Introduction
11.4.4 GlaxoSmithKline(U.K.) Revenue in Inactivated Vaccine Business (2020-2025)
11.4.5 GlaxoSmithKline(U.K.) Recent Development
11.5 Johnson & Johnson(U.S.)
11.5.1 Johnson & Johnson(U.S.) Company Details
11.5.2 Johnson & Johnson(U.S.) Business Overview
11.5.3 Johnson & Johnson(U.S.) Inactivated Vaccine Introduction
11.5.4 Johnson & Johnson(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
11.5.5 Johnson & Johnson(U.S.) Recent Development
11.6 MedImmune(U.S.)
11.6.1 MedImmune(U.S.) Company Details
11.6.2 MedImmune(U.S.) Business Overview
11.6.3 MedImmune(U.S.) Inactivated Vaccine Introduction
11.6.4 MedImmune(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
11.6.5 MedImmune(U.S.) Recent Development
11.7 Merck & Co(U.S.)
11.7.1 Merck & Co(U.S.) Company Details
11.7.2 Merck & Co(U.S.) Business Overview
11.7.3 Merck & Co(U.S.) Inactivated Vaccine Introduction
11.7.4 Merck & Co(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
11.7.5 Merck & Co(U.S.) Recent Development
11.8 Pfizer(U.S.)
11.8.1 Pfizer(U.S.) Company Details
11.8.2 Pfizer(U.S.) Business Overview
11.8.3 Pfizer(U.S.) Inactivated Vaccine Introduction
11.8.4 Pfizer(U.S.) Revenue in Inactivated Vaccine Business (2020-2025)
11.8.5 Pfizer(U.S.) Recent Development
11.9 Sanofi Pasteur(France)
11.9.1 Sanofi Pasteur(France) Company Details
11.9.2 Sanofi Pasteur(France) Business Overview
11.9.3 Sanofi Pasteur(France) Inactivated Vaccine Introduction
11.9.4 Sanofi Pasteur(France) Revenue in Inactivated Vaccine Business (2020-2025)
11.9.5 Sanofi Pasteur(France) Recent Development
11.10 Serum Institute of India Pvt(India)
11.10.1 Serum Institute of India Pvt(India) Company Details
11.10.2 Serum Institute of India Pvt(India) Business Overview
11.10.3 Serum Institute of India Pvt(India) Inactivated Vaccine Introduction
11.10.4 Serum Institute of India Pvt(India) Revenue in Inactivated Vaccine Business (2020-2025)
11.10.5 Serum Institute of India Pvt(India) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
FEATURED COMPANIES
Astellas Pharma (Japan)
CSL Limited (Australia)
Emergent BioSolutions (U.S.)
GlaxoSmithKline (U.K.)
Johnson& Johnson (U.S.)
MedImmune (U.S.)
Merck& Co (U.S.)
Pfizer (U.S.)
Sanofi Pasteur (France)
Serum Institute of India Pvt (India)
List of Tables
 Table 1. Global Inactivated Vaccine Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031
 Table 2. Key Players of Children Inactivated Vaccine
 Table 3. Key Players of Adult Inactivated Vaccine
 Table 4. Global Inactivated Vaccine Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031
 Table 5. Global Inactivated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 6. Global Inactivated Vaccine Market Size by Region (2020-2025) & (US$ Million)
 Table 7. Global Inactivated Vaccine Market Share by Region (2020-2025)
 Table 8. Global Inactivated Vaccine Forecasted Market Size by Region (2026-2031) & (US$ Million)
 Table 9. Global Inactivated Vaccine Market Share by Region (2026-2031)
 Table 10. Inactivated Vaccine Market Trends
 Table 11. Inactivated Vaccine Market Drivers
 Table 12. Inactivated Vaccine Market Challenges
 Table 13. Inactivated Vaccine Market Restraints
 Table 14. Global Inactivated Vaccine Revenue by Players (2020-2025) & (US$ Million)
 Table 15. Global Inactivated Vaccine Market Share by Players (2020-2025)
 Table 16. Global Top Inactivated Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2024)
 Table 17. Ranking of Global Top Inactivated Vaccine Companies by Revenue (US$ Million) in 2024
 Table 18. Global 5 Largest Players Market Share by Inactivated Vaccine Revenue (CR5 and HHI) & (2020-2025)
 Table 19. Global Key Players of Inactivated Vaccine, Headquarters and Area Served
 Table 20. Global Key Players of Inactivated Vaccine, Product and Application
 Table 21. Global Key Players of Inactivated Vaccine, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Inactivated Vaccine Market Size by Type (2020-2025) & (US$ Million)
 Table 24. Global Inactivated Vaccine Revenue Market Share by Type (2020-2025)
 Table 25. Global Inactivated Vaccine Forecasted Market Size by Type (2026-2031) & (US$ Million)
 Table 26. Global Inactivated Vaccine Revenue Market Share by Type (2026-2031)
 Table 27. Global Inactivated Vaccine Market Size by Application (2020-2025) & (US$ Million)
 Table 28. Global Inactivated Vaccine Revenue Market Share by Application (2020-2025)
 Table 29. Global Inactivated Vaccine Forecasted Market Size by Application (2026-2031) & (US$ Million)
 Table 30. Global Inactivated Vaccine Revenue Market Share by Application (2026-2031)
 Table 31. North America Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 32. North America Inactivated Vaccine Market Size by Country (2020-2025) & (US$ Million)
 Table 33. North America Inactivated Vaccine Market Size by Country (2026-2031) & (US$ Million)
 Table 34. Europe Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 35. Europe Inactivated Vaccine Market Size by Country (2020-2025) & (US$ Million)
 Table 36. Europe Inactivated Vaccine Market Size by Country (2026-2031) & (US$ Million)
 Table 37. Asia-Pacific Inactivated Vaccine Market Size Growth Rate by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 38. Asia-Pacific Inactivated Vaccine Market Size by Region (2020-2025) & (US$ Million)
 Table 39. Asia-Pacific Inactivated Vaccine Market Size by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 41. Latin America Inactivated Vaccine Market Size by Country (2020-2025) & (US$ Million)
 Table 42. Latin America Inactivated Vaccine Market Size by Country (2026-2031) & (US$ Million)
 Table 43. Middle East & Africa Inactivated Vaccine Market Size Growth Rate by Country (US$ Million): 2020 VS 2024 VS 2031
 Table 44. Middle East & Africa Inactivated Vaccine Market Size by Country (2020-2025) & (US$ Million)
 Table 45. Middle East & Africa Inactivated Vaccine Market Size by Country (2026-2031) & (US$ Million)
 Table 46. Astellas Pharma(Japan) Company Details
 Table 47. Astellas Pharma(Japan) Business Overview
 Table 48. Astellas Pharma(Japan) Inactivated Vaccine Product
 Table 49. Astellas Pharma(Japan) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 50. Astellas Pharma(Japan) Recent Development
 Table 51. CSL Limited(Australia) Company Details
 Table 52. CSL Limited(Australia) Business Overview
 Table 53. CSL Limited(Australia) Inactivated Vaccine Product
 Table 54. CSL Limited(Australia) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 55. CSL Limited(Australia) Recent Development
 Table 56. Emergent BioSolutions(U.S.) Company Details
 Table 57. Emergent BioSolutions(U.S.) Business Overview
 Table 58. Emergent BioSolutions(U.S.) Inactivated Vaccine Product
 Table 59. Emergent BioSolutions(U.S.) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 60. Emergent BioSolutions(U.S.) Recent Development
 Table 61. GlaxoSmithKline(U.K.) Company Details
 Table 62. GlaxoSmithKline(U.K.) Business Overview
 Table 63. GlaxoSmithKline(U.K.) Inactivated Vaccine Product
 Table 64. GlaxoSmithKline(U.K.) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 65. GlaxoSmithKline(U.K.) Recent Development
 Table 66. Johnson & Johnson(U.S.) Company Details
 Table 67. Johnson & Johnson(U.S.) Business Overview
 Table 68. Johnson & Johnson(U.S.) Inactivated Vaccine Product
 Table 69. Johnson & Johnson(U.S.) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 70. Johnson & Johnson(U.S.) Recent Development
 Table 71. MedImmune(U.S.) Company Details
 Table 72. MedImmune(U.S.) Business Overview
 Table 73. MedImmune(U.S.) Inactivated Vaccine Product
 Table 74. MedImmune(U.S.) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 75. MedImmune(U.S.) Recent Development
 Table 76. Merck & Co(U.S.) Company Details
 Table 77. Merck & Co(U.S.) Business Overview
 Table 78. Merck & Co(U.S.) Inactivated Vaccine Product
 Table 79. Merck & Co(U.S.) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 80. Merck & Co(U.S.) Recent Development
 Table 81. Pfizer(U.S.) Company Details
 Table 82. Pfizer(U.S.) Business Overview
 Table 83. Pfizer(U.S.) Inactivated Vaccine Product
 Table 84. Pfizer(U.S.) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 85. Pfizer(U.S.) Recent Development
 Table 86. Sanofi Pasteur(France) Company Details
 Table 87. Sanofi Pasteur(France) Business Overview
 Table 88. Sanofi Pasteur(France) Inactivated Vaccine Product
 Table 89. Sanofi Pasteur(France) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 90. Sanofi Pasteur(France) Recent Development
 Table 91. Serum Institute of India Pvt(India) Company Details
 Table 92. Serum Institute of India Pvt(India) Business Overview
 Table 93. Serum Institute of India Pvt(India) Inactivated Vaccine Product
 Table 94. Serum Institute of India Pvt(India) Revenue in Inactivated Vaccine Business (2020-2025) & (US$ Million)
 Table 95. Serum Institute of India Pvt(India) Recent Development
 Table 96. Research Programs/Design for This Report
 Table 97. Key Data Information from Secondary Sources
 Table 98. Key Data Information from Primary Sources
 Table 99. Authors List of This Report


List of Figures
 Figure 1. Inactivated Vaccine Picture
 Figure 2. Global Inactivated Vaccine Market Size Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Inactivated Vaccine Market Share by Type: 2024 VS 2031
 Figure 4. Children Inactivated Vaccine Features
 Figure 5. Adult Inactivated Vaccine Features
 Figure 6. Global Inactivated Vaccine Market Size by Application (2020-2031) & (US$ Million)
 Figure 7. Global Inactivated Vaccine Market Share by Application: 2024 VS 2031
 Figure 8. Hospital Case Studies
 Figure 9. Medical Center Case Studies
 Figure 10. Inactivated Vaccine Report Years Considered
 Figure 11. Global Inactivated Vaccine Market Size (US$ Million), Year-over-Year: 2020-2031
 Figure 12. Global Inactivated Vaccine Market Size, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Inactivated Vaccine Market Share by Region: 2024 VS 2031
 Figure 14. Global Inactivated Vaccine Market Share by Players in 2024
 Figure 15. Global Top Inactivated Vaccine Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Inactivated Vaccine as of 2024)
 Figure 16. The Top 10 and 5 Players Market Share by Inactivated Vaccine Revenue in 2024
 Figure 17. North America Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 18. North America Inactivated Vaccine Market Share by Country (2020-2031)
 Figure 19. United States Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 20. Canada Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 21. Europe Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 22. Europe Inactivated Vaccine Market Share by Country (2020-2031)
 Figure 23. Germany Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 24. France Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 25. U.K. Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 26. Italy Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 27. Russia Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 28. Nordic Countries Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 29. Asia-Pacific Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 30. Asia-Pacific Inactivated Vaccine Market Share by Region (2020-2031)
 Figure 31. China Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 32. Japan Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 33. South Korea Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 34. Southeast Asia Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 35. India Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 36. Australia Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 37. Latin America Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 38. Latin America Inactivated Vaccine Market Share by Country (2020-2031)
 Figure 39. Mexico Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 40. Brazil Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 41. Middle East & Africa Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 42. Middle East & Africa Inactivated Vaccine Market Share by Country (2020-2031)
 Figure 43. Turkey Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 44. Saudi Arabia Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 45. UAE Inactivated Vaccine Market Size YoY Growth (2020-2031) & (US$ Million)
 Figure 46. Astellas Pharma(Japan) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 47. CSL Limited(Australia) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 48. Emergent BioSolutions(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 49. GlaxoSmithKline(U.K.) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 50. Johnson & Johnson(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 51. MedImmune(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 52. Merck & Co(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 53. Pfizer(U.S.) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 54. Sanofi Pasteur(France) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 55. Serum Institute of India Pvt(India) Revenue Growth Rate in Inactivated Vaccine Business (2020-2025)
 Figure 56. Bottom-up and Top-down Approaches for This Report
 Figure 57. Data Triangulation
 Figure 58. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Accenture

SIMILAR REPORTS

Global Inactivated Poultry Vaccine Market Research Report 2025
Global Pet Inactivated Vaccine Market Research Report 2025
Global Poultry Killed Vaccines Market Research Report 2025
Poliovirus Vaccine Inactivated Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Travelers Vaccines Market Research Report 2025
Inactivated Poliovirus Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Travelers Vaccination Market Research Report 2025
Global Influenza Vaccine Split Virion Inactivated Quadrivalent Market Research Report 2024
Global Human Vaccination Market Research Report 2025
Global Human Vaccine Market Size Manufacturers Supply Chain Sales Channel and Clients 2024 2030
Global Viral Vector Vaccine for Humans Market Research Report 2024
Global Inactivated Influenza Virus Vaccine Market Research Report 2025
Global Bacterial Vaccines for Humans Market Research Report 2024
Global Live Inactivated Ruminants Vaccine Market Research Report 2024
Global Inactivated Poultry Vaccines Market Research Report 2024
Vaccine Include COVID 19 Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inactivated Hepatitis A Vaccine Market Research Report 2024
Global Poliomyelitis Vaccine Market Research Report 2025
Global Veterinary Biological Vaccines Market Research Report 2025
Global Veterinary Vaccination Market Research Report 2025
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions